• Nasus Pharma enrolled and dosed the first patient in a Phase 1 trial of NS003, an intranasal ondansetron product candidate.
• Preclinical work already showed drug exposure broadly comparable to IV ondansetron, with supportive safety findings at higher-than-test dosing.
• The Phase 1 study will generate first-in-human pharmacokinetic and safety readouts for NS003.
• Topline results have not been presented yet; data are expected before year-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290800PRIMZONEFULLFEED9835142) on September 29, 2026, and is solely responsible for the information contained therein.